Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28306

1.

Long-term outcome of high-risk prostate cancer treated with brachytherapy combined with external-beam radiation therapy and androgen deprivation therapy.

Chen J, Yan WG, Li HZ, Ji ZG, Zhou Y, Zhou ZE, Mai ZP.

Tumori. 2014 Sep-Oct;100(5):524-528. doi: 10.1700/1660.18170.

PMID:
25343547
[PubMed - as supplied by publisher]
2.

99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer.

Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ.

J Nucl Med. 2014 Oct 23. pii: jnumed.114.140426. [Epub ahead of print]

PMID:
25342385
[PubMed - as supplied by publisher]
3.

Diethylstilboestrol (1 mg) in the Management of Castration-Resistant Prostate Cancer.

Turo R, Tan K, Thygesen H, Sundaram SK, Chahal R, Prescott S, Cross WR.

Urol Int. 2014 Oct 21. [Epub ahead of print]

PMID:
25342383
[PubMed - as supplied by publisher]
4.

Radical prostatectomy versus external beam radiotherapy for localized prostate cancer : Comparison of treatment outcomes.

Kim YJ, Cho KH, Pyo HR, Lee KH, Moon SH, Kim TH, Shin KH, Kim JY, Kim YK, Lee SB.

Strahlenther Onkol. 2014 Oct 23. [Epub ahead of print]

PMID:
25339310
[PubMed - as supplied by publisher]
5.

Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer : An interim analysis of 312 cases.

Badakhshi H, Graf R, Budach V, Wust P.

Strahlenther Onkol. 2014 Oct 23. [Epub ahead of print]

PMID:
25339309
[PubMed - as supplied by publisher]
6.

Prediction of biochemical recurrence after robot-assisted radical prostatectomy: Analysis of 784 Japanese patients.

Hashimoto T, Yoshioka K, Nagao G, Nakagami Y, Ohno Y, Horiguchi Y, Namiki K, Nakashima J, Tachibana M.

Int J Urol. 2014 Oct 22. doi: 10.1111/iju.12624. [Epub ahead of print]

PMID:
25339062
[PubMed - as supplied by publisher]
7.

8q24 rs4242382 Polymorphism is a Risk Factor for Prostate Cancer among Multi-Ethnic Populations: Evidence from Clinical Detection in China and a Meta-analysis.

Zhao CX, Liu M, Xu Y, Yang K, Wei D, Shi XH, Yang F, Zhang YG, Wang X, Liang SY, Zhao F, Zhang YR, Wang NN, Chen X, Sun L, Zhu XQ, Yuan HP, Zhu L, Yang YG, Tang L, Jiao HY, Huo ZH, Wang JY, Yang Z.

Asian Pac J Cancer Prev. 2014;15(19):8311-7.

PMID:
25339022
[PubMed - in process]
Free Article
8.
9.

To screen or nor to screen: the prostate cancer dilemma.

Stone NN, Crawford ED.

Asian J Androl. 2014 Oct 3. doi: 10.4103/1008-682X.142770. [Epub ahead of print]

PMID:
25337849
[PubMed - as supplied by publisher]
10.

Ratio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer.

Zhang HM, Yan Y, Wang F, Gu WY, Hu GH, Zheng JH.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):6079-84. eCollection 2014.

PMID:
25337254
[PubMed - in process]
Free PMC Article
11.

Laparoscopic radical prostatectomy with bladder neck preservation: positive surgical margin and urinary continence status.

Golabek T, Jaskulski J, Jarecki P, Dudek P, Szopiński T, Chłosta P.

Wideochir Inne Tech Malo Inwazyjne. 2014 Sep;9(3):362-70. doi: 10.5114/wiitm.2014.45085. Epub 2014 Sep 5.

PMID:
25337159
[PubMed]
Free PMC Article
12.

Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy.

Hackett C, Ghosh S, Sloboda R, Martell K, Lan L, Pervez N, Pedersen J, Yee D, Murtha A, Amanie J, Usmani N.

J Contemp Brachytherapy. 2014 Oct;6(3):247-53. doi: 10.5114/jcb.2014.45093. Epub 2014 Sep 5.

PMID:
25337125
[PubMed]
Free PMC Article
13.

Prostate-specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer.

Lundon D, Loeb S.

Rev Urol. 2014;16(3):154-6. Review. No abstract available.

PMID:
25337050
[PubMed]
Free PMC Article
14.

Flexible Gold Electrode Array for Multiplexed Immunoelectrochemical Measurement of Three Protein Biomarkers for Prostate Cancer.

Liu J, Lu CY, Zhou H, Xu JJ, Chen HY.

ACS Appl Mater Interfaces. 2014 Oct 21. [Epub ahead of print]

PMID:
25333408
[PubMed - as supplied by publisher]
15.

End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review.

Colloca G, Venturino A, Governato I.

World J Methodol. 2014 Jun 26;4(2):123-32. doi: 10.5662/wjm.v4.i2.123. eCollection 2014 Jun 26.

PMID:
25332911
[PubMed]
Free PMC Article
16.

Advanced carcinoma of the prostate presenting as a supraclavicular mass: Case report.

Agbugui JO, Obarisiagbon EO, Ugiagbe EE.

Niger Postgrad Med J. 2014 Sep;21(3):269-71.

PMID:
25331247
[PubMed - in process]
17.

Synthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen.

Byun Y, Pullambhatla M, Wang H, Mease RC, Pomper MG.

Macromol Res. 2013 May 1;21(5):565-573.

PMID:
25328507
[PubMed]
Free PMC Article
18.

Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.

Mandl SJ, Rountree RB, Dela Cruz TB, Foy SP, Cote JJ, Gordon EJ, Trent E, Delcayre A, Franzusoff A.

J Immunother Cancer. 2014 Oct 14;2(1):34. doi: 10.1186/s40425-014-0034-0. eCollection 2014.

PMID:
25328681
[PubMed]
Free PMC Article
19.

Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.

DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E.

Prostate. 2014 Oct 18. doi: 10.1002/pros.22916. [Epub ahead of print]

PMID:
25327986
[PubMed - as supplied by publisher]
20.

Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.

Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC.

Prostate. 2014 Oct 18. doi: 10.1002/pros.22910. [Epub ahead of print]

PMID:
25327687
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk